Poster 25
- Kelley Tangredi
- May 25, 2024
- 1 min read
Updated: Jun 27, 2024
Interim Results from Admirable, A Phase 3b Open-Label Study Assessing Lebrikizumab in Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis
Authors: Andrew Alexis, Ali Moiin, Jill Waibel, Paul Wallace, David Cohen, Vivian Laquer, Pearl Kwong, Amber Reck Atwater, Cynthia Harris, Jennifer Proper, Maria Silk, Evangeline Pierce, Sreekumar Pillai, Maria Jose Rueda, Angela Moore
Poster 25